Physician profile
Michael J Carnathan
NPI 1851529093
$5,324.24
in general payments reported to CMS, 2019-2025
25 companies · $983 in 2025
The $983 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $753 · 2021: $806 · 2022: $738 · 2023: $682 · 2024: $692 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,828.99 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $1,207.40 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $493.14 | 2019-2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $352.79 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $219.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $214.52 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $190.09 | 2024-2025 | Veozah |
| Amarin Pharma, INC. | $171.49 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $138.26 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $100.41 | 2019-2021 | |
| Pfizer INC. | $91.06 | 2019-2021 | |
| Abbvie INC. | $43.32 | 2024-2025 | |
| Amgen INC. | $31.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.79 | 2023 | |
| Lundbeck LLC | $30.33 | 2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.17 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.85 | 2025 | Evkeeza |
| Shire North American Group INC | $19.18 | 2019 | |
| Philips North America LLC | $14.84 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.50 | 2019 | |
| Glaxosmithkline, LLC. | $13.69 | 2019 | |
| Echosens North America, INC. | $13.56 | 2024 | Fibroscan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carnathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.